{
    "nctId": "NCT01121549",
    "briefTitle": "A Non-Interventional Study With Aromasin\u00ae As Adjuvant Treatment Of Invasive Early Breast Cancer",
    "officialTitle": "A Non-Interventional Study With Aromasin\u00ae As Adjuvant Treatment Of Invasive Early Breast Cancer In Postmenopausal Hormone Receptors Positive Patients Following Of 2-3 Years of Initial Adjuvant Tamoxifen Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Invasive Early Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 378,
    "primaryOutcomeMeasure": "Number of Participants With Treatment-Emergent Adverse Events (AEs) by Severity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal females, defined as one from the next :\n\n  1. Natural menopause \\>/=1 year,\n  2. Surgical ovariectomy,\n  3. Chemotherapy-induced amenorrhoea \\>/=2 years.\n* Patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.\n* Patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.\n* Patients whose tumour was estrogen receptor positive (ER+).\n* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n\nExclusion Criteria:\n\n* Patients for whom Aromasin\u00ae treatment is contraindicated (see SmPC).\n* Presence of metastasis or a contra lateral tumour.\n* Other adjuvant endocrine therapy.\n* Another concomitant antineoplastic treatment\n* Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.\n* The patients are not supposed to participate to any other trial during all the study period.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}